NAP alpha-aminoisobutyric acid (IsoNAP)

Journal of Molecular Neuroscience

Volumn 52, Issue 1, 2014, Pages 1-9

  Gozes, Illana ^a   Schirer, Yulie ^a   Idan Feldman, Anat ^a   David, Merav ^a   Furman Assaf, Sharon ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

ADNP; ADNP deficiency; NAP (davunetide); NAP Alpha Aminoisobutyric Acid (IsoNAP); Neuroprotection; sheet breaker

Indexed keywords

2 AMINO 2 METHYLPROPIONIC ACID; AMYLOID BETA PROTEIN[1-42]; DAVUNETIDE; PROLINE; TAU PROTEIN;

ALZHEIMER DISEASE; AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BETA SHEET; BRAIN CELL CULTURE; CELL CULTURE; COGNITION; CONTROLLED STUDY; IN VITRO STUDY; MALE; MOUSE; NERVE DEGENERATION; NEUROPATHOLOGY; NEUROPROTECTION; NEUROTOXICITY; NEWBORN; NONHUMAN; PROTEIN AGGREGATION; PROTEIN DEFICIENCY; PROTEIN FOLDING; RAT; TAUOPATHY;

AMINOISOBUTYRIC ACIDS; AMYLOID BETA-PEPTIDES; ANIMALS; ASTROCYTES; CELLS, CULTURED; CEREBRAL CORTEX; HOMEODOMAIN PROTEINS; MAZE LEARNING; MICE; NERVE TISSUE PROTEINS; NEURONS; NEUROPROTECTIVE AGENTS; OLIGOPEPTIDES; PEPTIDE FRAGMENTS; RATS; TAU PROTEINS;

EID: 84895076670     PISSN: 08958696     EISSN: 15591166     Source Type: Journal    
DOI: 10.1007/s12031-013-0103-8     Document Type: Article

References (38)

1. Ashur-Fabian O, Segal-Ruder Y, Skutelsky E, Brenneman DE, Steingart RA, Giladi E, Gozes I (2003) The neuroprotective peptide NAP inhibits the aggregation of the beta-amyloid peptide. Peptides 24:1413-1423
2. Bassan M, Zamostiano R, Davidson A, Pinhasov A, Giladi E, Perl O, Bassan H, Blat C, Gibney G, Glazner G, Brenneman DE, Gozes I (1999) Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide. J Neurochem 72:1283-1293
3. Bour A, Grootendorst J, Vogel E, Kelche C, Dodart JC, Bales K, Moreau PH, Sullivan PM, Mathis C (2008) Middle-aged human apoE4 targeted-replacement mice show retention deficits on a wide range of spatial memory tasks. Behav Brain Res 193:174-182
4. Brandeis R, Brandys Y, Yehuda S (1989) The use of the Morris water maze in the study of memory and learning. Int J Neurosci 48:29-69
5. Brenneman DE, Spong CY, Hauser JM, Abebe D, Pinhasov A, Golian T, Gozes I (2004) Protective peptides that are orally active and mechanistically nonchiral. J Pharmacol Exp Ther 309:1190-1197
6. Divinski I, Mittelman L, Gozes I (2004) A femtomolar acting octapeptide interacts with tubulin and protects astrocytes against zinc intoxication. J Biol Chem 279:28531-28538
7. Friedhoff P, Schneider A, Mandelkow EM, Mandelkow E (1998) Rapid assembly of Alzheimer-like paired helical filaments from microtubule-associated protein tau monitored by fluorescence in solution. Biochemistry 37:10223-10230
8. Furman S, Hill JM, Vulih I, Zaltzman R, Hauser JM, Brenneman DE, Gozes I (2005) Sexual dimorphism of activity-dependent neuroprotective protein in the mouse arcuate nucleus. Neurosci Lett 373:73-78
9. Gilead S, Gazit E (2004) Inhibition of amyloid fibril formation by peptide analogues modified with alpha-aminoisobutyric acid. Angew Chem Int Ed Engl 43:4041-4044
10. Gold M, Lorenzl S, Stewart AJ, Morimoto BH, Williams DR, Gozes I (2012) Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy. Neuropsychiatr Dis Treat 8:85-93
11. Gozes I (2010) Davunetide (NAP) pharmacology: neuroprotection and tau. In: Martinez A (ed) Emerging drugs and targets for Alzheimer's disease, vol 3. Royal Society of Chemistry, Cambridge, pp 108-128
12. Gozes I (2011) NAP (davunetide) provides functional and structural neuroprotection. Curr Pharm Des 17:1040-1044
13. Gozes I, Baas PW (2013) Activity-dependent neuroprotective protein (ADNP) and davunetide (NAP). In: Kastin AJ (ed) Handbook of biologically active peptide (Illana Gozes editor of section XVIII, pp 1611-1653), 2nd edn. Academic Press, New York, pp 1611-1618
14. Gozes I, Divinski I, Piltzer I (2008) NAP and d-SAL: neuroprotection against beta amyloid peptide (1-42). Curr Alzheimer Res 9(Suppl 3):S3
15. Gozes I, Giladi E, Pinhasov A, Bardea A, Brenneman DE (2000) Activity-dependent neurotrophic factor: intranasal administration of femtomolar-acting peptides improve performance in a water maze. J Pharmacol Exp Ther 293:1091-1098
16. Gozes I, Morimoto BH, Tiong J, Fox A, Sutherland K, Dangoor D, Holser-Cochav M, Vered K, Newton P, Aisen PS, Matsuoka Y, van Dyck CH, Thal L (2005) NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP). CNS Drug Rev 11:353-368
17. Idan-Feldman A, Ostritsky R, Gozes I (2012) Tau and caspase 3 as targets for neuroprotection. Int J Alzheimers Dis 2012:493670
18. Jarskog LF, Dong Z, Kangarlu A, Colibazzi T, Girgis RR, Kegeles LS, Barch DM, Buchanan RW, Csernansky JG, Goff DC, Harms MP, Javitt DC, Keefe RS, McEvoy JP, McMahon RP, Marder SR, Peterson BS, Lieberman JA (2013) Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia. Neuropsychopharmacology 38:1245-1252
19. Javitt DC, Buchanan RW, Keefe RS, Kern R, McMahon RP, Green MF, Lieberman J, Goff DC, Csernansky JG, McEvoy JP, Jarskog F, Seidman LJ, Gold JM, Kimhy D, Nolan KS, Barch DS, Ball MP, Robinson J, Marder SR (2012) Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia. Schizophr Res 136:25-31
20. Jouroukhin Y, Ostritsky R, Assaf Y, Pelled G, Giladi E, Gozes I (2013) NAP (davunetide) modifies disease progression in a mouse model of severe neurodegeneration: protection against impairments in axonal transport. Neurobiol Dis 56C:79-94
21. Jouroukhin Y, Ostritsky R, Gozes I (2012) d-NAP prophylactic treatment in the SOD mutant mouse model of amyotrophic lateral sclerosis: review of discovery and treatment of tauopathy. J Mol Neurosci 48:597-602
22. Leker RR, Shohami E, Constantini S (2002) Experimental models of head trauma. Acta Neurochir Suppl 83:49-54
23. Matsuoka Y, Gray AJ, Hirata-Fukae C, Minami SS, Waterhouse EG, Mattson MP, LaFerla FM, Gozes I, Aisen PS (2007) Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage. J Mol Neurosci 31:165-170
24. Matsuoka Y, Jouroukhin Y, Gray AJ, Ma L, Hirata-Fukae C, Li HF, Feng L, Lecanu L, Walker BR, Planel E, Arancio O, Gozes I, Aisen PS (2008) A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease. J Pharmacol Exp Ther 325:146-153
25. Merenlender-Wagner A, Pikman R, Giladi E, Andrieux A, Gozes I (2010) NAP (davunetide) enhances cognitive behavior in the STOP heterozygous mouse - a microtubule-deficient model of schizophrenia. Peptides 31:1368-1373
26. Morimoto BH, de Lannoy I, Fox AW, Gozes I, Stewart AJ (2009) Davunetide: pharmacokinetics and distribution to brain after intravenous or intranasal administration to rat. Chimica Oggi/Chemistry Today 27:16-20
27. Morris R (1984) Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 11:47-60
28. Oz S, Ivashko-Pachima Y, Gozes I (2012) The ADNP derived peptide, NAP modulates the tubulin pool: implication for neurotrophic and neuroprotective activities. PLoS One 7:e51458
29. Perez M, Santa-Maria I, Tortosa E, Cuadros R, Del Valle M, Hernandez F, Moreno FJ, Avila J (2007) The role of the VQIVYK peptide in tau protein phosphorylation. J Neurochem 103:1447-1460
30. Pinhasov A, Mandel S, Torchinsky A, Giladi E, Pittel Z, Goldsweig AM, Servoss SJ, Brenneman DE, Gozes I (2003) Activity-dependent neuroprotective protein: a novel gene essential for brain formation. Brain Res Dev Brain Res 144:83-90
31. Quraishe S, Cowan CM, Mudher A (2013) NAP (davunetide) rescues neuronal dysfunction in a Drosophila model of tauopathy. Mol Psychiatry 18:834-842
32. Shiryaev N, Jouroukhin Y, Giladi E, Polyzoidou E, Grigoriadis NC, Rosenmann H, Gozes I (2009) NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model. Neurobiol Dis 34:381-388
33. Shiryaev N, Pikman R, Giladi E, Gozes I (2011) Protection against tauopathy by the drug candidates NAP (davunetide) and D-SAL: biochemical, cellular and behavioral aspects. Curr Pharm Des 17:2603-2612
34. Sudo H, Baas PW (2011) Strategies for diminishing katanin-based loss of microtubules in tauopathic neurodegenerative diseases. Hum Mol Genet 20:763-778
35. von Bergen M, Friedhoff P, Biernat J, Heberle J, Mandelkow EM, Mandelkow E (2000) Assembly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif ((306)VQIVYK(311)) forming beta structure. Proc Natl Acad Sci U S A 97:5129-5134
36. Vulih-Shultzman I, Pinhasov A, Mandel S, Grigoriadis N, Touloumi O, Pittel Z, Gozes I (2007) Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model. J Pharmacol Exp Ther 323:438-449
37. Wilkemeyer MF, Chen SY, Menkari CE, Brenneman DE, Sulik KK, Charness ME (2003) Differential effects of ethanol antagonism and neuroprotection in peptide fragment NAPVSIPQ prevention of ethanol-induced developmental toxicity. Proc Natl Acad Sci U S A 100:8543-8548
38. Zemlyak I, Furman S, Brenneman DE, Gozes I (2000) A novel peptide prevents death in enriched neuronal cultures. Regul Pept 96:39-43